Ultragenyx Pharmaceutical
RARE
#5300
Rank
C$2.33 B
Marketcap
C$22.96
Share price
-1.17%
Change (1 day)
-49.69%
Change (1 year)

Earnings for Ultragenyx Pharmaceutical (RARE)

Earnings in 2026 (TTM): -C$0.63 Billion

According to Ultragenyx Pharmaceutical's latest financial reports the company's current earnings are C$0.73 Billion. In 2025 the company made an earning of -C$0.73 Billion a decrease over its 2024 earnings that were of -C$0.73 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Ultragenyx Pharmaceutical from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -C$0.63 Billion-14.01%
2025 -C$0.73 Billion0.93%
2024 -C$0.73 Billion-6.99%
2023 -C$0.78 Billion-17.65%
2022 -C$0.95 Billion55.52%
2021 -C$0.61 Billion178.53%
2020 -C$0.22 Billion-59.64%
2019 -C$0.54 Billion1.46%
2018 -C$0.54 Billion12.9%
2017 -C$0.47 Billion32.63%
2016 -C$0.36 Billion67.87%
2015 -C$0.22 Billion160.2%
2014 -C$81.07 Million66.64%
2013 -C$48.65 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Lexicon Pharmaceuticals
LXRX
-C$87.26 Million-86.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
C$0.11 B-117.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
C$0.27 M-100.04%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
C$62.33 M-109.76%๐Ÿ‡บ๐Ÿ‡ธ USA